Corvus Pharmaceuticals share price logo

Corvus Pharmaceuticals

NASDAQ: CRVS

Small Cap

$14.20

-0.07

(-0.49%)

as on

Corvus Pharmaceuticals Stock Performance

as on September 3, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $13.87
    $14.82
    downward going graph

    2.32%

    Downside

    4.37%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.58
    $26.95
    downward going graph

    60.70%

    Downside

    89.79%

    Upside

    downward going graph

Corvus Pharmaceuticals share price movements today

Previous Close
$14.27
Open
$14.42
Volume
481.6K
Market Cap
$1.2B
Day's Low - High
$13.87 - $14.82
52 Week Low - High
$5.58 - $26.95

Corvus Pharmaceuticals Historical Returns

1 Month Return
+ 7.62 %
3 Month Return
+ 22.07 %
1 Year Return
+ 151.68 %
3 Year Return
+ 569.95 %
5 Year Return
+ 424.63 %

Corvus Pharmaceuticals Stock Fundamentals & Key Indicators

Check Corvus Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

-0.7775

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-56.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-35.43%

Corvus Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Corvus Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Corvus Pharmaceuticals image
Corvus Pharmaceuticals
BUY$1.2B424.63%NA0.00%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$137.9B174.9%31.9286.04%NA
Moderna image
Moderna
BUY$61.6B-61.21%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.3B21.91%19.984.86%0.44%

Stock Returns calculator for Corvus Pharmaceuticals Stock including INR - Dollar returns

The Corvus Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Corvus Pharmaceuticals investment value today

Current value as on today

₹2,70,255

Returns

₹1,70,255

(+170.25%)

Returns from Corvus Pharmaceuticals Stock

₹1,50,441 (+150.44%)

Dollar Impact

₹19,814 (+19.81%)

Analyst Recommendation on Corvus Pharmaceuticals Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Corvus Pharmaceuticals. Average target price of $33.14

Corvus Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Corvus Pharmaceuticals.

What analysts predicted

57.15%UPSIDE

Target Price

$33.14

Current Price

$14.2

Analyzed by

4 Analysts

Target

$33.14

Corvus Pharmaceuticals target price $33.14, a slight upside of 57.15% compared to current price of $14.2. According to 4 analysts rating.

Indian Investors' Interest in Corvus Pharmaceuticals Stock

Search interest for Corvus Pharmaceuticals Stock has increased by 26% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:26% versus previous 30 day period

Corvus Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
0
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
-
0
0
-
Operating Income
-6
-5
-7
-8
-9
-10
-10
-12
-14
-19
EBITDA
-5
-4
-40
-12
15
-7
-10
-12
-11
-17
Interest Expense
0
0
0
-
0
0
0
2
1
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-5
-4
-40
-12
15
-7
-10
-12
-13
-17
Income Tax Expense
0
-
-
-
-
-
-
-
-
0
Net Income
-5
-4
-40
-12
15
-7
-10
-12
-13
-17
Net Profit Margin
0.00%
0.00%
0.00%
-13764.77%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Corvus Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-36
-56
-49
-48
-43
-38
-32
-23
-27
-42
EBITDA
-36
-55
-48
-48
-43
-42
-40
-26
-62
-15
Interest Expense
0
-
2
2
0
0
0
1
1
2
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-36
-55
-46
-46
-5
-43
-41
-27
-62
-15
Income Tax Expense
0
0
2
-2
-1
-5
8
-
-
-
Net Income
-36
-55
-46
-43
-4
-43
-41
-27
-62
-15
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Corvus Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-4
-40
-12
15
-7
-10
-12
-13
-17
Operating Cash Flow
-5
-6
-8
-8
-5
-9
-9
-10
-15
Investing Cash Flow
-17
-3
-6
4
-20
-2
10
-144
-5
Financing Cash Flow
30
0
18
0
35
0
0
190
0
Change in Cash
7
-10
4
-3
9
-11
1
35
-21

Corvus Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-55
-46
-46
-5
-43
-41
-27
-62
-15
Operating Cash Flow
-46
-40
-37
-34
-36
-27
-23
-25
-32
Investing Cash Flow
84
-30
3
44
21
-23
15
-27
-7
Financing Cash Flow
1
65
0
1
62
0
7
49
36
Change in Cash
40
-5
-34
11
47
-50
0
-3
-4

Mutual Funds that own Corvus Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Corvus Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.756458%
3159968
Manager Directed Portfolios
0.884552%
744094
Fidelity Concord Street Trust
0.872722%
734142
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
0.861972%
725099
T. ROWE PRICE NEW HORIZONS FUND, INC.
0.858623%
722282
See all

Global Institutional Holdings in Corvus Pharmaceuticals

Funds
Holdings
Vanguard
4.85%
iShares
4.29%
SPDR
4%
Joseph Edelman
3.17%
Peter Kolchinsky
0.53%
See all

Corvus Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 20 January

    Wed, 00:30 AM

    -

    Corvus Pharmaceuticals shares surged 140% after positive Phase 1 trial results for soquelitinib in atopic dermatitis.

Insights on Corvus Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, CRVS stock has moved up by 152.7%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CRVS has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 527.1% return, outperforming this stock by 374.4%

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
OrganisationCorvus Pharmaceuticals
Headquarters901 Gateway Boulevard, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEODr. Richard A. Miller M.D.
E-voting on sharesClick here to vote

Key Management of Corvus Pharmaceuticals

Name

Title

Dr. Richard A. Miller M.D.

Co-Founder, President, CEO & Chairman of the Board

Dr. Peter A. Thompson FACP, M.D.

Co-Founder & Independent Director

Mr. Leiv Lea

Chief Financial Officer

Dr. William Benton Jones Ph.D.

Senior Vice President of Pharmaceutical Development

Mr. Jeffrey S. Arcara

Senior VP & Chief Business Officer

FAQs

What is Corvus Pharmaceuticals share price today?

Corvus Pharmaceuticals share price today is $14.20 as on at the close of the market. Corvus Pharmaceuticals share today touched a day high of $14.82 and a low of $13.87.

What is the 52 week high and 52 week low for Corvus Pharmaceuticals share?

Corvus Pharmaceuticals share touched a 52 week high of $26.95 on and a 52 week low of $5.58 on . Corvus Pharmaceuticals stock price today i.e. is closed at $14.20,which is 47.31% down from its 52 week high and 154.48% up from its 52 week low.

What is Corvus Pharmaceuticals's market capitalisation today?

Corvus Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Corvus Pharmaceuticals Stock (CRVS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Corvus Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Corvus Pharmaceuticals Shares that will get you 0.1056 shares as per Corvus Pharmaceuticals share price of $14.20 per share as on September 3, 2026 at 8:46 am IST.

What is the minimum amount required to buy Corvus Pharmaceuticals Stock (CRVS) from India?

Indian investors can start investing in Corvus Pharmaceuticals (CRVS) shares with as little as ₹94.96 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Corvus Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Corvus Pharmaceuticals share’s latest price of $14.20 as on September 3, 2026 at 8:46 am IST, you will get 0.7042 shares of Corvus Pharmaceuticals. Learn more about fractional shares .

What are the returns that Corvus Pharmaceuticals has given to Indian investors in the last 5 years?

Corvus Pharmaceuticals stock has given 424.63% share price returns and 30.36% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?